Nxera Pharma Co., Ltd.- Nxera Pharma's Partner Neurocrine Biosciences Receives IND Acceptance From FDA For Phase 2 Study Of NBI-1117567 For Alzheimer's Cognition
NBIX•FDA accepts IND for Neurocrine's phase 2 Alzheimer's cognition study
Aug. 26 (Reuters) - Nxera Pharma Co., Ltd. 4565.T:
- Nxera Pharma's partner Neurocrine Biosciences received IND acceptance from the U.S. Food and Drug Administration (FDA) for a phase 2 study of NBI-1117567 for Alzheimer's cognition.
- Nxera will receive an IND acceptance milestone payment of US$10 million from Neurocrine pursuant to the agreement.
- The milestone payment is expected to be recognised in full as revenue in Q3 FY2026.
